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SCIENTIFIC OPINION 
Scientific Opinion on the substantiation of health claims related to 
sodium alginate and reduction of post-prandial glycaemic responses 
(ID 1868, 1881) pursuant to Article 13(1) of Regulation (EC) No 1924/2006
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European Food Safety Authority (EFSA), Parma, Italy 
SUMMARY 
Following a request from the European Commission, the Panel on Dietetic Products, Nutrition and 
Allergies was asked to provide a scientific opinion on a list of health claims pursuant to Article 13 of 
Regulation (EC) No 1924/2006. This opinion addresses the scientific substantiation of health claims 
in relation to sodium alginate and reduction of post-prandial glycaemic responses. The scientific 
substantiation is based on the information provided by the Member States in the consolidated list of 
Article 13 health claims and references that EFSA has received from Member States or directly from 
stakeholders. 
The food constituent that is the subject of the health claim is “sodium alginate and Ascophyllum 
nodosum”. From the references provided, the Panel assumes that the food constituent that is the 
subject of the health claim is sodium alginate. The Panel considers that sodium alginate with an M/G 
ratio of 1.50 is sufficiently characterised in relation to the claimed effect. 
The claimed effect is “alginate can reduce the activity of digestive enzymes and reduce glucose 
absorption”. The target population is assumed to be subjects who wish to reduce their post-prandial 
glycaemic responses. The Panel considers that the reduction of post-prandial glycaemic responses (as 
long as post-prandial insulinaemic responses are not disproportionally increased) may be a beneficial 
physiological effect. 
In weighing the evidence, the Panel took into account that the one human intervention study provided 
from which conclusions could be drawn for the scientific substantiation of the claim did not show a 
reduction in post-prandial glycaemic responses without a disproportionate increase in post-prandial 
insulinaemic responses following consumption of sodium alginate. 
                                                     
1  On request from the European Commission, Question No EFSA-Q-2008-2601, EFSA-Q-2008-2614, adopted on 
25 March 2011. 
2  Panel members: Carlo Agostoni, Jean-Louis Bresson, Susan Fairweather-Tait, Albert Flynn, Ines Golly, Hannu Korhonen, 
Pagona Lagiou, Martinus Løvik, Rosangela Marchelli, Ambroise Martin, Bevan Moseley, Monika Neuhäuser-Berthold, 
Hildegard Przyrembel, Seppo Salminen, Yolanda Sanz, Sean (J.J.) Strain, Stephan Strobel, Inge Tetens, Daniel Tomé, 
Hendrik van Loveren and Hans Verhagen. Correspondence: nda@efsa.europa.eu 
3 Acknowledgement: The Panel wishes to thank for the preparatory work on this scientific opinion: The members of the 
Working Group on Claims: Carlo Agostoni, Jean-Louis Bresson, Susan Fairweather-Tait, Albert Flynn, Ines Golly, Marina 
Heinonen, Hannu Korhonen, Martinus Løvik, Ambroise Martin, Hildegard Przyrembel, Seppo Salminen, Yolanda Sanz, 
Sean (J.J.) Strain, Inge Tetens, Hendrik van Loveren and Hans Verhagen. The members of the Claims Sub-Working Group 
on Weight Management/Satiety/Glucose and Insulin Control/Physical Performance: Kees de Graaf, Joanne Harrold, Mette 
Hansen, Mette Kristensen, Anders Sjödin and Inge Tetens. 
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On the basis of the data presented, the Panel concludes that a cause and effect relationship has not 
been established between the consumption of sodium alginate and the reduction of post-prandial 
glycaemic responses without disproportionally increasing post-prandial insulinaemic responses.  
KEY WORDS 
Sodium alginate, post-prandial glycaemic response, insulin, health claims. 
Sodium alginate and reduction of post-prandial glycaemic responses 
 
3 EFSA Journal 2011;9(6):2261 
TABLE OF CONTENTS 
Summary .................................................................................................................................................. 1 
Table of contents ...................................................................................................................................... 3 
Background as provided by the European Commission .......................................................................... 4 
Terms of reference as provided by the European Commission ............................................................... 4 
EFSA Disclaimer...................................................................................................................................... 4 
Information as provided in the consolidated list ...................................................................................... 5 
Assessment ............................................................................................................................................... 5 
1. Characterisation of the food/constituent (ID 1868, 1881) ............................................................... 5 
2. Relevance of the claimed effect to human health (ID 1868, 1881) ................................................. 5 
3. Scientific substantiation of the claimed effect (ID 1868, 1881) ..................................................... 6 
Conclusions .............................................................................................................................................. 7 
Documentation provided to EFSA ........................................................................................................... 7 
References ................................................................................................................................................ 7 
Appendices ............................................................................................................................................... 8 
Glossary and Abbreviations ................................................................................................................... 15 
 
Sodium alginate and reduction of post-prandial glycaemic responses 
 
4 EFSA Journal 2011;9(6):2261 
BACKGROUND AS PROVIDED BY THE EUROPEAN COMMISSION 
See Appendix A 
TERMS OF REFERENCE AS PROVIDED BY THE EUROPEAN COMMISSION 
See Appendix A 
EFSA DISCLAIMER 
See Appendix B 
Sodium alginate and reduction of post-prandial glycaemic responses 
 
5 EFSA Journal 2011;9(6):2261 
INFORMATION AS PROVIDED IN THE CONSOLIDATED LIST 
The consolidated list of health claims pursuant to Article 13 of Regulation (EC) No 1924/2006
4
 
submitted by Member States contains main entry claims with corresponding conditions of use and 
literature for similar health claims. EFSA has screened all health claims contained in the original 
consolidated list of Article 13 health claims which was received by EFSA in 2008 using six criteria 
established by the NDA Panel to identify claims for which EFSA considered sufficient information 
had been provided for evaluation and those for which more information or clarification was needed 
before evaluation could be carried out
5
. The clarifications which were received by EFSA through the 
screening process have been included in the consolidated list. This additional information will serve 
as clarification to the originally provided information. The information provided in the consolidated 
list for the health claims which are the subject of this opinion is tabulated in Appendix C. 
ASSESSMENT 
1. Characterisation of the food/constituent (ID 1868, 1881) 
The food constituent that is the subject of the health claim is “sodium alginate and Ascophyllum 
nodosum”. 
Sodium alginate is the sodium salt of alginic acid. Sodium alginate is extracted from the cell walls of 
brown algae. It is authorised for use as a food additive
6
 (E 401) for its thickening and emulsifying 
properties. 
Alginate is an anionic polysaccharide, a linear copolymer with homopolymeric blocks of 
(1-4)-linked -D-mannuronate (M) and its epimer -glucuronate (G) residues, which are linked 
covalently in different sequences. Commercial varieties of sodium alginate are extracted from 
Marocystis pyrifera, Ascophyllum nodosum and various types of Laminaria. Different sources yield 
alginates that differ in monomeric composition and block structure, and a given alginate has its own 
characteristic calcium reactivity and gelation properties. Alginates are usually referred to as high M or 
high G, depending on the proportions of M and G they contain. Although the food constituent that is 
the subject of the health claim is indicated to be sodium alginate from Ascophyllum nodosum, the 
human studies provided for the scientific substantiation of the health claim do not indicate the source 
of the sodium alginate used. 
From the references provided, the Panel assumes that the food constituent that is the subject of the 
health claims is sodium alginate with an M/G ratio of 1.50. This opinion refers to sodium alginate 
with an M/G ratio of 1.50 from all sources. 
The Panel considers that the food constituent, sodium alginate, which is the subject of the health 
claim, is sufficiently characterised in relation to the claimed effect. 
2. Relevance of the claimed effect to human health (ID 1868, 1881) 
The claimed effect is “alginate can reduce the activity of digestive enzymes and reduce glucose 
absorption”, and “polyphenols found in Ascophyllum nodosum inhibit enzyme activity and reduce the 
                                                     
4  Regulation (EC) No 1924/2006 of the European Parliament and of the Council of 20 December 2006 on nutrition and 
health claims made on foods. OJ L 404, 30.12.2006, p. 9–25. 
5  EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA), 2011. General guidance for stakeholders on the 
evaluation of Article 13.1, 13.5 and 14 health claims. EFSA Journal, 9(4):2135, 24 pp. 
6  European Parliament and Council Directive 95/2/EC of 20 February 1995, on food additives other than colours and 
sweeteners. OJ L 61, 18.3.1995, p. 1–40. 
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glycaemic load of meals”. The Panel assumes that the target population is individuals who wish to 
reduce their post-prandial glycaemic responses. 
In the context of the proposed wordings and the references provided, the Panel assumes that the 
claimed effect refers to the reduction of post-prandial glycaemic responses. 
Postprandial glycaemia is interpreted as the elevation of blood glucose concentrations after 
consumption of a food and/or meal. This is a normal physiological response that varies in magnitude 
and duration, and which may be influenced by the chemical and physical nature of the food or meal 
consumed, as well as by individual factors (Venn and Green, 2007). Reducing post-prandial blood 
glucose responses may be beneficial to subjects with, for example, impaired glucose tolerance, as 
long as post-prandial insulinaemic responses are not disproportionally increased. Impaired glucose 
tolerance and hyperinsulinaemia are common in the general population of adults. 
The Panel considers that the reduction of post-prandial glycaemic responses (as long as post-prandial 
insulinaemic responses are not disproportionally increased) may be a beneficial physiological effect. 
3. Scientific substantiation of the claimed effect (ID 1868, 1881) 
Among the references provided were one narrative review and three animal studies which were not 
related to the claimed effect, and one animal study which did not address the food constituent that is 
the subject of the claim. The Panel considers that no conclusions can be drawn from these references 
for the scientific substantiation of the claim. 
One placebo-controlled, cross-over intervention study (Torsdottir et al., 1991) investigated the effects 
of 5 g sodium alginate (M/G ratio of 1.50) consumed in a meal on post-prandial glycaemic and 
insulinaemic responses in seven men with non-insulin dependent diabetes mellitus. Three of the 
subjects were treated with sulfonylurea. The evidence provided does not establish that subjects with 
non-insulin dependent diabetes mellitus under treatment with sulfonylurea are representative of the 
target population with respect to their insulinaemic responses to carbohydrate-containing meals. The 
Panel considers that no conclusions can be drawn from this reference for the scientific substantiation 
of the claim.  
In a double-blind, placebo-controlled, cross-over intervention study (Wolf et al., 2002), 30 healthy 
adult subjects (19 women) consumed a 250 g glucose-based beverage containing 1.5 g 
sodium alginate with an M/G ratio of 1.50/100 g beverage, and the same beverage containing no 
sodium alginate but 1.2 g gum Arabic and 0.3 g guar gum/100 g beverage after an overnight 12 h fast, 
on two different occasions, 12 days apart. Subjects were instructed to eat a high carbohydrate diet (at 
least 200 g/day) for the three days before each testing session and were allowed to drink 250 mL 
water during the 3 h test. Subjects consumed the test and control beverages within 10 min, and blood 
sampling was performed at baseline and 15, 30, 60, 90, 120 and 180 minutes post-prandial. 
Incremental peak glucose response was used for power calculations, and was the primary outcome of 
the study. Net incremental areas under the curve (AUC) for blood glucose and insulin concentrations 
were calculated with the trapezoidal rule, ignoring the area below fasting blood glucose values. Mean 
incremental peak glucose response was not significantly different between beverages, whereas the 
mean incremental peak insulin response was significantly higher with the test compared to the control 
beverage (p<0.05). The net incremental AUC for glucose was significantly lower for the test than for 
the control (p<0.01). The time at which peak glucose was reached was not significantly different, but 
incremental glucose concentrations were significantly lower at 60 and 150 min for the test compared 
to the control (p<0.05). No significant differences were observed between beverages with respect to 
the net incremental AUC for insulin. However, incremental insulin concentrations were significantly 
higher at 90 min for the test compared to the control (p<0.01). The Panel notes that this study does not 
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show an effect of sodium alginate on the reduction of post-prandial blood glucose responses without 
disproportionally increasing post-prandial insulin responses. 
One animal study investigated a possible mechanism by which sodium alginate could exert an effect 
on post-prandial glycaemic responses. The Panel considers that evidence provided in animal studies is 
not sufficient to predict the occurrence of an effect of sodium alginate consumption on the reduction 
of post-prandial glycaemic responses in humans. 
In weighing the evidence, the Panel took into account that the one human intervention study provided 
from which conclusions could be drawn for the scientific substantiation of the claim did not show a 
reduction in post-prandial glycaemic responses without a disproportionate increase in post-prandial 
insulinaemic responses following consumption of sodium alginate. 
The Panel concludes that a cause and effect relationship has not been established between the 
consumption of sodium alginate and the reduction of post-prandial glycaemic responses without 
disproportionally increasing post-prandial insulinaemic responses.  
CONCLUSIONS  
On the basis of the data presented, the Panel concludes that: 
 The food constituent, sodium alginate (with an M/G ratio of 1.50), which is the subject of the 
health claim, is sufficiently characterised in relation to the claimed effect. 
 The claimed effect is “alginate can reduce the activity of digestive enzymes and reduce 
glucose absorption”. The target population is assumed to be individuals who wish to reduce 
their post-prandial glycaemic responses. A reduction of post-prandial glycaemic responses (as 
long as post-prandial insulinaemic responses are not disproportionally increased) may be a 
beneficial physiological effect. 
 A cause and effect relationship has not been established between the consumption of 
sodium alginate and the reduction of post-prandial glycaemic responses without 
disproportionally increasing post-prandial insulinaemic responses. 
DOCUMENTATION PROVIDED TO EFSA 
Health claims pursuant to Article 13 of Regulation (EC) No 1924/2006 (No: EFSA-Q-2008-2601, 
EFSA-Q-2008-2614). The scientific substantiation is based on the information provided by the 
Member States in the consolidated list of Article 13 health claims and references that EFSA has 
received from Member States or directly from stakeholders. 
The full list of supporting references as provided to EFSA is available on: 
http://www.efsa.europa.eu/panels/nda/claims/article13.htm. 
REFERENCES 
Torsdottir I, Alpsten M, Holm G, Sandberg AS and Tolli J, 1991. A small dose of soluble alginate-
fiber affects postprandial glycemia and gastric emptying in humans with diabetes. Journal of 
Nutrition, 121, 795-799. 
Wolf BW, Lai CS, Kipnes MS, Ataya DG, Wheeler KB, Zinker BA, Garleb KA and Firkins JL, 2002. 
Glycemic and insulinemic responses of nondiabetic healthy adult subjects to an experimental acid-
induced viscosity complex incorporated into a glucose beverage. Nutrition, 18, 621-626. 
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APPENDICES 
APPENDIX A 
BACKGROUND AND TERMS OF REFERENCE AS PROVIDED BY THE EUROPEAN COMMISSION 
The Regulation 1924/2006 on nutrition and health claims made on foods
7
 (hereinafter "the 
Regulation") entered into force on 19
th
 January 2007. 
Article 13 of the Regulation foresees that the Commission shall adopt a Community list of permitted 
health claims other than those referring to the reduction of disease risk and to children's development 
and health. This Community list shall be adopted through the Regulatory Committee procedure and 
following consultation of the European Food Safety Authority (EFSA). 
Health claims are defined as "any claim that states, suggests or implies that a relationship exists 
between a food category, a food or one of its constituents and health". 
In accordance with Article 13 (1) health claims other than those referring to the reduction of disease 
risk and to children's development and health are health claims describing or referring to:  
a) the role of a nutrient or other substance in growth, development and the functions of the 
body; or 
b) psychological and behavioural functions; or 
c) without prejudice to Directive 96/8/EC, slimming or weight-control or a reduction in the 
sense of hunger or an increase in the sense of satiety or to the reduction of the available 
energy from the diet. 
To be included in the Community list of permitted health claims, the claims shall be: 
(i) based on generally accepted scientific evidence; and 
(ii) well understood by the average consumer. 
Member States provided the Commission with lists of claims as referred to in Article 13 (1) by 31 
January 2008 accompanied by the conditions applying to them and by references to the relevant 
scientific justification. These lists have been consolidated into the list which forms the basis for the 
EFSA consultation in accordance with Article 13 (3). 
ISSUES THAT NEED TO BE CONSIDERED 
IMPORTANCE AND PERTINENCE OF THE FOOD
8
  
Foods are commonly involved in many different functions
9
 of the body, and for one single food many 
health claims may therefore be scientifically true. Therefore, the relative importance of food e.g. 
nutrients in relation to other nutrients for the expressed beneficial effect should be considered: for 
functions affected by a large number of dietary factors it should be considered whether a reference to 
a single food is scientifically pertinent. 
                                                     
7 OJ L12, 18/01/2007 
8 The term 'food' when used in this Terms of Reference refers to a food constituent, the food or the food category.  
9 The term 'function' when used in this Terms of Reference refers to health claims in Article 13(1)(a), (b) and (c).  
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It should also be considered if the information on the characteristics of the food contains aspects 
pertinent to the beneficial effect. 
SUBSTANTIATION OF CLAIMS BY GENERALLY ACCEPTABLE SCIENTIFIC EVIDENCE 
Scientific substantiation is the main aspect to be taken into account to authorise health claims. Claims 
should be scientifically substantiated by taking into account the totality of the available scientific 
data, and by weighing the evidence, and shall demonstrate the extent to which: 
(a) the claimed effect of the food is beneficial for human health, 
(b) a cause and effect relationship is established between consumption of the food and the 
claimed effect in humans (such as: the strength, consistency, specificity, dose-
response, and biological plausibility of the relationship), 
(c) the quantity of the food and pattern of consumption required to obtain the claimed 
effect could reasonably be achieved as part of a balanced diet, 
(d) the specific study group(s) in which the evidence was obtained is representative of the 
target population for which the claim is intended. 
EFSA has mentioned in its scientific and technical guidance for the preparation and presentation of 
the application for authorisation of health claims consistent criteria for the potential sources of 
scientific data. Such sources may not be available for all health claims. Nevertheless it will be 
relevant and important that EFSA comments on the availability and quality of such data in order to 
allow the regulator to judge and make a risk management decision about the acceptability of health 
claims included in the submitted list. 
The scientific evidence about the role of a food on a nutritional or physiological function is not 
enough to justify the claim. The beneficial effect of the dietary intake has also to be demonstrated. 
Moreover, the beneficial effect should be significant i.e. satisfactorily demonstrate to beneficially 
affect identified functions in the body in a way which is relevant to health. Although an appreciation 
of the beneficial effect in relation to the nutritional status of the European population may be of 
interest, the presence or absence of the actual need for a nutrient or other substance with nutritional or 
physiological effect for that population should not, however, condition such considerations. 
Different types of effects can be claimed. Claims referring to the maintenance of a function may be 
distinct from claims referring to the improvement of a function. EFSA may wish to comment whether 
such different claims comply with the criteria laid down in the Regulation. 
WORDING OF HEALTH CLAIMS 
Scientific substantiation of health claims is the main aspect on which EFSA's opinion is requested. 
However, the wording of health claims should also be commented by EFSA in its opinion. 
There is potentially a plethora of expressions that may be used to convey the relationship between the 
food and the function. This may be due to commercial practices, consumer perception and linguistic 
or cultural differences across the EU. Nevertheless, the wording used to make health claims should be 
truthful, clear, reliable and useful to the consumer in choosing a healthy diet. 
In addition to fulfilling the general principles and conditions of the Regulation laid down in Article 3 
and 5, Article 13(1)(a) stipulates that health claims shall describe or refer to "the role of a nutrient or 
other substance in growth, development and the functions of the body". Therefore, the requirement to 
Sodium alginate and reduction of post-prandial glycaemic responses 
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describe or refer to the 'role' of a nutrient or substance in growth, development and the functions of 
the body should be carefully considered. 
The specificity of the wording is very important. Health claims such as "Substance X supports the 
function of the joints" may not sufficiently do so, whereas a claim such as "Substance X helps 
maintain the flexibility of the joints" would. In the first example of a claim it is unclear which of the 
various functions of the joints is described or referred to contrary to the latter example which 
specifies this by using the word "flexibility". 
The clarity of the wording is very important. The guiding principle should be that the description or 
reference to the role of the nutrient or other substance shall be clear and unambiguous and therefore 
be specified to the extent possible i.e. descriptive words/ terms which can have multiple meanings 
should be avoided. To this end, wordings like "strengthens your natural defences" or "contain 
antioxidants" should be considered as well as "may" or "might" as opposed to words like 
"contributes", "aids" or "helps".  
In addition, for functions affected by a large number of dietary factors it should be considered 
whether wordings such as "indispensable", "necessary", "essential" and "important" reflects the 
strength of the scientific evidence. 
Similar alternative wordings as mentioned above are used for claims relating to different relationships 
between the various foods and health. It is not the intention of the regulator to adopt a detailed and 
rigid list of claims where all possible wordings for the different claims are approved. Therefore, it is 
not required that EFSA comments on each individual wording for each claim unless the wording is 
strictly pertinent to a specific claim. It would be appreciated though that EFSA may consider and 
comment generally on such elements relating to wording to ensure the compliance with the criteria 
laid down in the Regulation. 
In doing so the explanation provided for in recital 16 of the Regulation on the notion of the average 
consumer should be recalled. In addition, such assessment should take into account the particular 
perspective and/or knowledge in the target group of the claim, if such is indicated or implied. 
TERMS OF REFERENCE 
HEALTH CLAIMS OTHER THAN THOSE REFERRING TO THE REDUCTION OF DISEASE RISK AND TO 
CHILDREN'S DEVELOPMENT AND HEALTH 
EFSA should in particular consider, and provide advice on the following aspects: 
 Whether adequate information is provided on the characteristics of the food pertinent to the 
beneficial effect. 
 Whether the beneficial effect of the food on the function is substantiated by generally 
accepted scientific evidence by taking into account the totality of the available scientific data, 
and by weighing the evidence. In this context EFSA is invited to comment on the nature and 
quality of the totality of the evidence provided according to consistent criteria. 
 The specific importance of the food for the claimed effect. For functions affected by a large 
number of dietary factors whether a reference to a single food is scientifically pertinent. 
In addition, EFSA should consider the claimed effect on the function, and provide advice on the 
extent to which: 
 the claimed effect of the food in the identified function is beneficial. 
 a cause and effect relationship has been established between consumption of the food and the 
claimed effect in humans and whether the magnitude of the effect is related to the quantity 
consumed. 
Sodium alginate and reduction of post-prandial glycaemic responses 
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 where appropriate, the effect on the function is significant in relation to the quantity of the 
food proposed to be consumed and if this quantity could reasonably be consumed as part of a 
balanced diet.  
 the specific study group(s) in which the evidence was obtained is representative of the target 
population for which the claim is intended. 
 the wordings used to express the claimed effect reflect the scientific evidence and complies 
with the criteria laid down in the Regulation.  
When considering these elements EFSA should also provide advice, when appropriate: 
 on the appropriate application of Article 10 (2) (c) and (d) in the Regulation, which provides 
for additional labelling requirements addressed to persons who should avoid using the food; 
and/or warnings for products that are likely to present a health risk if consumed to excess. 
Sodium alginate and reduction of post-prandial glycaemic responses 
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APPENDIX B 
EFSA DISCLAIMER 
The present opinion does not constitute, and cannot be construed as, an authorisation to the marketing 
of the food/food constituent, a positive assessment of its safety, nor a decision on whether the 
food/food constituent is, or is not, classified as foodstuffs. It should be noted that such an assessment 
is not foreseen in the framework of Regulation (EC) No 1924/2006. 
It should also be highlighted that the scope, the proposed wordings of the claims and the conditions of 
use as proposed in the Consolidated List may be subject to changes, pending the outcome of the 
authorisation procedure foreseen in Article 13(3) of Regulation (EC) No 1924/2006. 
Sodium alginate and reduction of post-prandial glycaemic responses 
 
13 EFSA Journal 2011;9(6):2261 
APPENDIX C 
Table 1. Main entry health claims related to sodium alginate, including conditions of use from similar 
claims, as proposed in the Consolidated List. 
ID Food or Food constituent Health Relationship Proposed wording 
1868 Name of Food product: 
Product-specific claim: 
sodium alginate and 
ascophyllum nodosum. 
Health benefits of food: Alginate 
can reduce the activity of 
digestive enzymes and reduce 
glucose absorption. Polyphenols 
found in ascophyllum nodosum 
inhibit enzyme activity and 
reduce the glycaemic load of 
meals. 
Do benefits relate to a disease 
risk factor: Yes. 
Target group: Adults aged 18 
years and over with some 
exceptions. 
If exceptions describe: Pregnant, 
lactating women and children. 
People with brittle bones or 
calcium deficiency. 
Reasons for excluding these 
groups: Sodium alginate may 
decrease the absorption of 
calcium if taken concomitantly 
therefore it should be avoided by 
pregnant, lactating women and 
children and those with brittle 
bones or calcium defiency. 
Exact wording of claim as it 
appears on product: Helps 
manage blood glucose levels. 
Examples of any alternative 
wording that may be used in 




load of a meal/Helps 
maintain a normal blood 
glucose level as part of a 
healthly lifestyle/Contributes 




of normal glucose levels. 
Conditions of use 
 Number of nutrients/other substances that are essential to claimed effect: 2. Names of 
nutrient/other substances and Quantity in Average daily serving: 5 grams sodium alginate, 1 
gram ascophyllum nodosum. Weight of average daily food serving: 150 mililitre(s). Daily 
amount to be consumed to produce claimed effect: 300 mililitre(s). Number of food portions 
this equates to in everyday food portions: 1.00. Are there factors that could interfere with 
bioavailability: No. Length of time after consumption for claimed effect to become 
apparent: 4 weeks. Is there a limit to the amount of food which should be consumed in order 
to avoid adverse health effects: No. Where applicable outline nutritional composition (g per 
100g) of food:  Total Fat: .01, Saturated Fat: .00, Trans Fat: .00, Sugar: .31, Salt: .00, 
Sodium: .01 Other conditions for use: This beverage should be consumed as part of a 
varied, balanced, healthy lifestyle. Two beverages are to be consumed daily in order to gain 
benefit. The entire beverage must be consumed. This product should be avoided by pregnant 
and lactating women, children and those brittle bones and calcium deficiency. 
ID Food or Food constituent Health Relationship Proposed wording 
1881 Name of Food product: 
Product-specific claim: 
Sodium alginate and 
Health benefits of food: Alginate 
can reduce the activity of 
digestive enzymes and reduce 
Exact wording of claim as it 
appears on product: Helps 
manage blood glucose and 
Sodium alginate and reduction of post-prandial glycaemic responses 
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ascophyllum nodosum. glucose absorption. Polyphenols 
found in ascophyllulm nodosum 
inhibit enzyme activity and 
reduce the glycemic load of 
meals. 
Do benefits relate to a disease 
risk factor: Yes. 
Target group: Adults aged 18 
years and over with some 
exceptions. 
If exceptions describe: Pregnant, 
lactating women and children. 
People with brittle bones or 
calcium deficiency. 
Reasons for excluding these 
groups: Sodium alginate may 
decrease the absorption of 
calcium if taken concomitantly 
therefore it should be avoided by 
pregnant, lactating women and 
children and those with brittle 
bones or calcium deficiency. 
insulin levels. 
Examples of any alternative 
wording that may be used in 
relation to claim: Reduces 
heightened glycaemic 
index/Blunts glucose and 
insuin elevation/Reduces the 
glycaemic load of a 
meal/Helps maintain a 
normal blood glucose level as 
part of a healthy 
lifestyle/Contributes to 
normal blood glucose levels 






of normal glucose levels. 
Is claim a picture: No. 
Conditions of use 
 Number of nutrients/other substances that are essential to claimed effect: 2. Names of 
nutrient/other substances and Quantity in Average daily serving: 5 grams sodium algiante, 1 
grams ascophyllum nodosum. Weight of average daily food serving: 150 mililitre(s). Daily 
amount to be consumed to produce claimed effect: 300 mililitre(s). Number of food portions 
this equates to in everyday food portions: 1. Are there factors that could interfere with 
bioavailability: No. Length of time after consumption for claimed effect to become 
apparent: 4 weeks. Is there a limit to the amount of food which should be consumed in order 
to avoid adverse health effects: No. Where applicable outline nutritional composition (g per 
100g) of food:  Total Fat: .01, Saturated Fat: .00, Trans Fat: .00, Sugar: .31, Salt: .00, 
Sodium: .01 Other conditions for use: This beverage should be consumed as part of a 
varied, balanced and healthy lifestyle. Two beverages are to be consumed daily in order to 
gain benefit. The entire beverage must be consumed. This product should be avoided by 
pregnant and lactating women, children and those with brittle bones and calcium deficiency. 
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GLOSSARY AND ABBREVIATIONS 
AUC  Areas under the curve 
M/G ratio (1-4)-linked -D-mannuronate/ -glucuronate ratio 
